期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
基于网络药理学和分子对接研究化湿行瘀清热方治疗口腔扁平苔藓的作用机制 被引量:1
1
作者 邓倩澜 路月亭 +4 位作者 路华林 靳睿哲 许彦枝 刘铁军 赵乾 《河北中医》 2021年第7期1195-1204,共10页
目的研究化湿行瘀清热方治疗口腔扁平苔藓的主要活性成分和分子机制。方法基于TCMSP数据库,BATMAN-TCM数据库和UniProt数据库筛选化湿行瘀清热方药物关键活性成分和对应靶点,应用GeneCards数据库获得疾病基因,Cytoscape软件用于构建“药... 目的研究化湿行瘀清热方治疗口腔扁平苔藓的主要活性成分和分子机制。方法基于TCMSP数据库,BATMAN-TCM数据库和UniProt数据库筛选化湿行瘀清热方药物关键活性成分和对应靶点,应用GeneCards数据库获得疾病基因,Cytoscape软件用于构建“药物-疾病调控网络”,使用String数据库进行蛋白互作网络构建(PPI),运用R语言数据包进行基因本体论(GO)和京都基因和基因组百科全书(KEGG)富集分析,预测其作用机制,最后使用AutoDock对化湿行瘀清热方中的关键活性化合物与PPI中的核心蛋白进行分子对接验证。结果从化湿行瘀清热方中筛选出169个活性成分和260个治疗靶点,在GeneCards数据库中鉴定出387个有关口腔扁平苔藓的疾病靶点。两者取交集后,共得到58个药物-疾病共同靶标,化合物-疾病调控网络显示关键药物成分为槲皮素、木犀草素、汉黄芩素和山奈酚等。核心PPI包括蛋白激酶B1(Akt1)、血管内皮生长因子A(VEGFA)、肿瘤坏死因子(TNF)、细胞间黏附因子-1(ICAM-1)、基质金属蛋白酶9(MMP-9)等14个关键疾病靶点,共富集了2169个GO和131个KEGG项目,涉及炎症、感染、代谢、肿瘤等多种途径,其中白细胞介素17(IL-17)信号通路与TNF信号通路与口腔扁平苔藓的发生密切相关。分子对接结果表明,关键药物成分槲皮素、木犀草素、汉黄芩素和山奈酚能够与Akt1、VEGFA、TNF、ICAM-1、MMP-9等14个关键疾病靶点结合,并表现出良好的亲和力。结论化湿行瘀清热方通过多成分、多靶点治疗口腔扁平苔藓,作用机制可能与IL-17信号通路和TNF信号通路相关。 展开更多
关键词 扁平苔癣 口腔 中药疗法 分子对接模拟
下载PDF
局部应用他克莫司治疗糜烂型口腔扁平苔藓的Meta-分析 被引量:2
2
作者 路华林 路月亭 +2 位作者 邓倩澜 许彦枝 刘铁军 《药物评价研究》 CAS 2020年第11期2291-2300,共10页
目的系统的评价外用他克莫司(软膏或漱口水)治疗糜烂型口腔扁平苔藓的有效性和安全性。方法计算机检索PubMed、EMbase、Cochrane Library、OVID、中国学术期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、维普中文期刊全文数据库(V... 目的系统的评价外用他克莫司(软膏或漱口水)治疗糜烂型口腔扁平苔藓的有效性和安全性。方法计算机检索PubMed、EMbase、Cochrane Library、OVID、中国学术期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、维普中文期刊全文数据库(VIP)和万方数据库,检索年限均为数据库建库至2019年12月,搜索他克莫司(软膏或漱口水)与皮质类固醇药物(对照药)比较治疗糜烂型口腔扁平苔藓的临床随机对照试验(RCTs),采用Stata1 4.2软件进行Meta-分析。结果共纳入23个RCTs、共1 269例患者。Meta-分析结果显示:与对照组比较治疗组有效率(RR=1.11,95%CI=1.02~1.22,P=0.022)及安全性(RR=0.62,95%CI=0.44~0.88,P=0.007)均有统计学差异(P<0.05),其中0.03%他克莫司比0.1%他克莫司更安全。结论治疗糜烂型口腔扁平苔藓,他克莫司较皮质类固醇药物的安全性更好,不良反应更低。 展开更多
关键词 他克莫司 口腔扁平苔藓 皮质类固醇 有效性 安全性 META-分析
原文传递
Mechanism of Huashi Xingyu Qingre recipe(化湿行淤清热方)in treating oral lichen planus based on network pharmacology and clinical trial verification
3
作者 deng qianlan LU Yueting +5 位作者 YAN Lijuan LU Hualin JIN Ruizhe XU Yanzhi SONG Jing LIU Tiejun 《Journal of Traditional Chinese Medicine》 SCIE CSCD 2022年第2期304-313,共10页
OBJECTIVE:To identify the main active components and targets of Huashi Xingyu Qingre recipe(化湿行淤清热方,HXQR)and to investigate its mechanism in the treatment of oral lichen planus(OLP).METHODS:The Traditional Chin... OBJECTIVE:To identify the main active components and targets of Huashi Xingyu Qingre recipe(化湿行淤清热方,HXQR)and to investigate its mechanism in the treatment of oral lichen planus(OLP).METHODS:The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform was searched to identify the active ingredients and corresponding targets of HXQR.Disease genes were obtained from the Gene Cards database,and a“drugdisease regulatory network”was constructed using Cytoscape software and PERL programming language.The STRING database was used to build a protein-protein interaction network.Gene ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)terms were analyzed using R software with a Bioconducter plugin.Finally,the results and the efficacy of HXQR in treating OLP were validated in a clinical trial that included enzyme-linked immunosorbent assay(ELISA)testing and observations of the post-treatment changes in clinical symptoms.RESULTS:HXQR contained 167 active components and 261 targets,with 391 disease targets.The intersection of these two categories in a Venn diagram revealed 57 drugdisease common targets.A compound-target network was constructed and revealed that the six key pharmaceutical ingredients of HXQR were quercetin,luteolin,wogonin,kaempferol,beta-carotene,and baicalein.The protein-protein interaction network mainly involved core proteins such as ALB,interleukin-6,and AKT1.Drug-disease common targets were enriched in 1628 GO terms and 117 KEGG terms,mainly involving inflammatory responses,viral infections,and tumorrelated pathways.ELISA testing indicated that HXQR inhibited the tumor necrosis factor(TNF)signaling pathway by reducing the expression of interleukin-6,matrix metalloproteinase-9,and intercellular adhesion molecule-1.The clinical symptoms of the patients with OLP were significantly improved after 8 weeks of treatment with HXQR.CONCLUSION:HXQR treats OLP by regulating the TNF signaling pathway,resulting in a marked treatment effect with few adverse effects. 展开更多
关键词 lichen planus ORAL network pharmacology clinical trial Huashi Xingyu Qingre recipe
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部